IOL Chemicals and Pharmaceuticals liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

6.59×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.78×	1.78×	1.89×	2.00×	2.02×
1.24×	1.24×	1.30×	1.24×	1.30×
68.9	68.9	81.5	10.6	4.0
537	537	541	560	464

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

IOLCP₹184.93

IOL Chemicals and Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersMOREPENLAB FDC INNOVACAP ORCHPHARMA SENORES SANOFI GUJTHEM RPGLIFEMcap ₹5,429 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	6.59
Current Ratio	2.02	2.00	1.89	1.78	1.78
Quick Ratio	1.30	1.24	1.30	1.24	1.24
Cash, Equiv & ST Investments	4.0	10.6	81.5	68.9	68.9
Working Capital	464.1	559.8	541.4	537.5	537.5

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.